Van Eck Associates Corp Neurocrine Biosciences Inc Transaction History

Van Eck Associates Corp

$88.3 Billion
Q2 2025

A detailed history of Van Eck Associates Corp transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Van Eck Associates Corp holds 107,854 shares of NBIX stock, worth $14.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

107,854

Previous 89,079 21.08%

Holding current value

$14.9 Million

Previous $9.85 Million 37.59%

% of portfolio

0.02%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$87.54 - $128.18 $1.64 Million - $2.41 Million	18,775 Added 21.08%	107,854 $13.6 Million
Q1 2025 May 15, 2025	SELL	$107.22 - $153.29 $463,940 - $663,285	-4,327 Reduced 4.63%	89,079 $9.85 Million
Q4 2024 Jan 29, 2025	BUY	$111.62 - $139.44 $1.1 Million - $1.37 Million	9,824 Added 11.75%	93,406 $12.8 Million
Q3 2024 Oct 29, 2024	SELL	$114.58 - $153.15 $1.45 Million - $1.94 Million	-12,637 Reduced 13.13%	83,582 $9.62 Million
Q2 2024 Jul 31, 2024	BUY	$130.86 - $143.19 $520,299 - $569,323	3,976 Added 4.31%	96,219 $13.2 Million
Q1 2024 Apr 30, 2024	BUY	$130.4 - $143.74 $11.2 Million - $12.3 Million	85,772 Added 1325.48%	92,243 $12.7 Million
Q4 2023 Feb 05, 2024	SELL	$106.07 - $132.76 $116,464 - $145,770	-1,098 Reduced 14.51%	6,471 $853,000
Q3 2023 Nov 08, 2023	SELL	$94.02 - $117.1 $139,055 - $173,190	-1,479 Reduced 16.35%	7,569 $852,000
Q2 2023 Aug 03, 2023	SELL	$89.53 - $104.87 $83,979 - $98,368	-938 Reduced 9.39%	9,048 $853,000
Q1 2023 May 03, 2023	BUY	$94.11 - $123.02 $939,782 - $1.23 Million	9,986 New	9,986 $1.01 Million
Q3 2021 Nov 03, 2021	SELL	$86.18 - $99.03 $9.77 Million - $11.2 Million	-113,390 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$89.43 - $102.27 $790,382 - $903,862	8,838 Added 8.45%	113,390 $11 Million
Q1 2021 May 13, 2021	BUY	$87.57 - $119.4 $46,412 - $63,282	530 Added 0.51%	104,552 $10.2 Million
Q4 2020 Feb 09, 2021	BUY	$86.91 - $108.33 $1.46 Million - $1.82 Million	16,789 Added 19.25%	104,022 $9.97 Million
Q3 2020 Nov 12, 2020	SELL	$96.16 - $135.15 $949,099 - $1.33 Million	-9,870 Reduced 10.16%	87,233 $8.39 Million
Q2 2020 Aug 10, 2020	BUY	$85.09 - $130.36 $2.07 Million - $3.17 Million	24,354 Added 33.48%	97,103 $11.8 Million
Q1 2020 May 12, 2020	SELL	$75.11 - $113.76 $2.34 Million - $3.54 Million	-31,139 Reduced 29.97%	72,749 $6.3 Million
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $11,804 - $16,125	136 Added 0.13%	103,888 $11.2 Million
Q3 2019 Nov 08, 2019	BUY	$83.82 - $101.5 $123,131 - $149,103	1,469 Added 1.44%	103,752 $9.35 Million
Q2 2019 Aug 07, 2019	SELL	$72.24 - $91.27 $829,531 - $1.05 Million	-11,483 Reduced 10.09%	102,283 $8.64 Million
Q1 2019 May 13, 2019	SELL	$69.31 - $91.53 $482,605 - $637,323	-6,963 Reduced 5.77%	113,766 $10 Million
Q4 2018 Feb 12, 2019	SELL	$68.32 - $124.36 $59,096 - $107,571	-865 Reduced 0.71%	120,729 $8.62 Million
Q3 2018 Nov 13, 2018	SELL	$98.88 - $125.85 $192,618 - $245,155	-1,948 Reduced 1.58%	121,594 $15 Million
Q2 2018 Aug 13, 2018	BUY	$75.3 - $105.99 $1.45 Million - $2.05 Million	19,302 Added 18.52%	123,542 $12.1 Million
Q1 2018 May 11, 2018	SELL	$75.88 - $92.43 $1.91 Million - $2.33 Million	-25,155 Reduced 19.44%	104,240 $8.65 Million
Q4 2017 Feb 12, 2018	SELL	$58.53 - $77.59 $8.37 Million - $11.1 Million	-142,977 Reduced 52.49%	129,395 $10 Million
Q3 2017 Nov 09, 2017	BUY	$47.97 - $61.28 $2.68 Million - $3.42 Million	55,810 Added 25.77%	272,372 $16.7 Million
Q2 2017 Aug 11, 2017	BUY	N/A	216,562	216,562 $9.96 Million

Others Institutions Holding NBIX

# of Institutions

681

Shares Held

102M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Neurocrine Biosciences Inc Transaction History